We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

31 hedge funds and large institutions have $1.04M invested in Gyre Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

30% more capital invested

Capital invested by funds: $796K → $1.04M (+$240K)

11% more funds holding

Funds holding: 28 → 31 (+3)

0.02% less ownership

Funds ownership: 0.4% → 0.38% (-0.02%)

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

Holders
31
Holders Change
+3
Holders Change %
+10.71%
% of All Funds
0.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
6
Reduced
8
Closed
3
Calls
$44K
Puts
–
Net Calls
+$44K
Net Calls Change
+$16K

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$92.4K
2
Citadel Advisors
Citadel Advisors
Florida
+$21.4K
3
Morgan Stanley
Morgan Stanley
New York
+$9.66K
4
TSS
Two Sigma Securities
New York
+$8.95K
5
AWA
Arete Wealth Advisors
Illinois
+$4.84K

Top Sellers

1
Renaissance Technologies
Renaissance Technologies
New York
-$82K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$35.8K
3
VF
Virtu Financial
New York
-$17K
4
Bank of America
Bank of America
North Carolina
-$11.6K
5
UBS Group
UBS Group
Switzerland
-$9.33K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$285K -$82K -12,247 -24%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$125K -$5.04K -752 -4%
Vanguard Group
3
Vanguard Group
Pennsylvania
$99.8K +$92.4K +13,793 New
BlackRock
4
BlackRock
New York
$74.2K +$47 +7 +0.1%
Morgan Stanley
5
Morgan Stanley
New York
$47.1K +$9.66K +1,443 +28%
KCM
6
Kynam Capital Management
New Jersey
$43.4K +$80 +12 +0.2%
Northern Trust
7
Northern Trust
Illinois
$41.7K – – –
State Street
8
State Street
Massachusetts
$35K – – –
NCM
9
Nantahala Capital Management
Connecticut
$32.7K – – –
JJ
10
Johnson & Johnson
New Jersey
$32.3K – – –
Acadian Asset Management
11
Acadian Asset Management
Massachusetts
$30K -$35.8K -5,349 -56%
Barclays
12
Barclays
United Kingdom
$29K – – –
Citadel Advisors
13
Citadel Advisors
Florida
$23.1K +$21.4K +3,198 New
Group One Trading
14
Group One Trading
Illinois
$22.6K -$937 -140 -4%
Parallax Volatility Advisers
15
Parallax Volatility Advisers
California
$21.1K -$6.94K -1,037 -26%
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$20.4K -$5.67K -847 -23%
CCM
17
Colorado Capital Management
Colorado
$16K – – –
HSBC Holdings
18
HSBC Holdings
United Kingdom
$15.7K – – –
Bank of America
19
Bank of America
North Carolina
$10.8K -$11.6K -1,732 -54%
TSS
20
Two Sigma Securities
New York
$9.66K +$8.95K +1,336 New
RJA
21
Raymond James & Associates
Florida
$6.22K – – –
AWA
22
Arete Wealth Advisors
Illinois
$5.23K +$4.84K +723 New
JP Morgan Chase
23
JP Morgan Chase
New York
$3.4K +$3.13K +467 +15,567%
UBS Group
24
UBS Group
Switzerland
$2.45K -$9.33K -1,393 -80%
CG
25
Cutler Group
California
$2K – – –
1
2

GYRE Hedge Fund Activity: Q3 2023 in Review

31 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2023, worth a combined $1.04M — up 30% from $796K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new GYRE positions and 3 closed out — a net gain of 3 holders — while 6 added to existing stakes and 8 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $92.4K. The largest seller was Renaissance Technologies, cutting an estimated $82K.

  • 31 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2023, up from 28 in Q2 2023.
  • Funds reported $1.04M of Gyre Therapeutics stock for Q3 2023, up 30% quarter-over-quarter.
  • 6 funds opened new Gyre Therapeutics positions in Q3 2023 and 3 closed out, a net change of +3 holders.
  • The largest Gyre Therapeutics buyer in Q3 2023 was Vanguard Group, an estimated $92.4K added.
  • The largest Gyre Therapeutics seller in Q3 2023 was Renaissance Technologies, an estimated $82K sold.

Based on aggregated 13F filings for Q3 2023.